Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

This study is testing a new drug combination (HS-10516 plus other treatments) for people with advanced kidney cancer (clear cell renal cell carcinoma) that has continued growing or spread despite previous treatment. Researchers want to find out if this combination is safe and effective. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic clear cell kidney cancer - Your cancer got worse during or after at least one prior treatment - You have at least one measurable tumor on scans - You are well enough to carry out daily activities (ECOG 0–1) - Your expected survival is more than 12 weeks - You are willing to use contraception during and for 12 months after treatment **You may NOT be eligible if...** - You have previously used lenvatinib or HIF inhibitors - You have active or spreading brain metastases - You have severe, uncontrolled heart disease, diabetes, or high blood pressure - Your blood oxygen level is below 92% - You have had a second primary cancer - You recently had major surgery or received other cancer therapy Talk to your doctor to see if this trial is right for you.